EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent first-line standard of care in unresectable <i>EGFR</i> mutation-positive (<i>EGFR</i>m+) non-small cell lung cancer (NSCLC).